Compare AstraZeneca plc (AZN) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Quantum Computing Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Quantum Computing Inc trades at $8.93 (market cap $2.03B). The key difference: AstraZeneca plc is far larger — about 122.2× Quantum Computing Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| AZN | QUBT | |
|---|---|---|
Market Cap | $248.14B | $2.03B |
Sector | Health | Technology |
52-Week High | $209.48 | $24.62 |
52-Week Low | $147.06 | $6.31 |
Enterprise Value | $275.41B | $1.09B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Quantum Computing Inc. (QUBT) trades at $8.91, down 0.22% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of $5.6 million, a significant increase year-over-year, though it posted a net loss. Analyst sentiment is positive with a 75% buy rating and a consensus price target of $18.50, suggesting substantial upside potential from current levels.
QUBT presents high-risk, high-reward potential as it transitions to commercial scaling, with strong revenue growth offset by persistent losses and negative margins. Key risks include execution challenges in manufacturing expansion and intense competition in the quantum computing sector. The stock's valuation remains steep with a P/S ratio of 189.05, requiring careful monitoring of profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
